The company revised its 2025 outlook to organic net sales growth of minus 2% to minus 2.5%, citing softer-than-expected OTC consumption in the U.S. and Europe and a slower recovery in Infant Formula.
Patrick Lockwood-Taylor, President and CEO, opened by highlighting progress on Perrigo's Three-S Plan to "Stabilize, Streamline and Strengthen One Perrigo," noting "We have taken significant steps in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback